

Supplemental Table 1: post-transplantation estimated GFR according to *de novo* DSA status

	No <i>dn</i> DSA (n=34)	C1q- <i>dn</i> DSA (n=5)	C1q+ <i>dn</i> DSA (n=7)	p
Post-transplantation MDRD eGFR (ml/min/1,73 m², mean ± SD)				
1 year	52.3 ± 15.3	50.0 ± 18.1	54.8 ± 23.2	ns
2 years	51.9 ± 17.0	49.2 ± 13.0	48.5 ± 29.1	ns
5 years	50.9 ± 17.7	45.8 ± 15.4	44.5 ± 20.6	ns

Supplemental Table 2: Patient characteristics of the first external validation cohort originating from the Hospices Civils de Lyon, Hôpital Edouard Herriot (n=295)

Patient characteristics	Mean ± SD or n (%)
Age (year, mean ± SD)	48 ± 14
Female/male (%)	88/203 (30/70)
Sensitized patients (%)	0 (0%)
Dialysis duration (month, mean ± SD)	31 ± 28
Primary transplant (%)	291 (97%)
HLA A-B-DR mismatches	3.4 ± 1.2
Immunosuppressive drugs at Day 0 (%)	
Daclizumab / Thymoglobulin / No	48 (16) / 214 (73) / 33 (11)
Ciclosporine A / Tacrolimus / Sirolimus	225 (76) / 61 (21) / 7 (2)
MMF / Azathioprine	286 (97) / 7 (2)
Follow-up (month, mean ± SD)	88 ± 27